

Eascra Biotech Selected for ISS National Lab Igniting Innovation Program to Study Cancer Treatment Delivery in Low Orbit

NASA and ISS National Lab funding Eascra Biotech's research supporting Cancer Moonshot Initiative

Boston, July 30, 2024 – [Eascra Biotech](#) was selected for the Igniting Innovation: Science in Space to Cure Disease on Earth program to study a new application for their Janus Base Nanoparticles (JBNps). Administrated by the Center for the Advancement of Science in Space, Inc. (CASIS), which manages the ISS National Lab, and NASA, the award could include up to \$7M for selected partners to conduct research on the International Space Station to support the Cancer Moonshot Initiative.

The ISS National Lab announced Eascra's selection for the award at the International Space Station Research & Development Conference (ISSRDC) in Boston today. Mari Anne Snow, CEO and cofounder and Yupeng Chen, cofounder and scientist advisor of Eascra who created the Janus base nanomaterial (JBN), joined NASA and ISS National Lab leaders on stage for the announcement.

"This award will allow us to advance cancer treatments for solid tumor cancers like breast and ovarian cancer. Using our Janus base nanoparticle (JBNp) as a delivery mechanism to directly target tumors, we aim to reduce the systemic exposure to patients for better treatment results with fewer side effects," said Mari Anne Snow, CEO of Eascra Biotech.

Eascra's JBNps are an entirely new type of nanotube particle delivery platform inspired by DNA. The platform delivers RNA therapeutics to hard-to-reach treatment sites like joints. Low Earth orbit and microgravity allow the JBNps to assemble under optimal conditions, creating high-quality, consistent, and orderly structures that vastly improve efficiency. Once assembled, the nanomaterials, JBNps safe and stable delivery vehicles for RNA therapies, gene editing, and vaccines.

About Eascra Biotech

Eascra Biotech (eascrabiotech.com) is an early-stage nanomedicine startup providing an advanced therapeutic delivery platform capable of delivering RNA, gene editing, and other therapeutics to hard-to-reach treatment sites, such as cartilage, solid tumors, and other cells. Our mission is to advance science for the benefit of humankind. Eascra's proprietary delivery mechanism, a Janus Base Nanoparticle (JBNp) invented by Eascra co-founder, Dr. Yupeng Chen, inspired by DNA and is customizable for different treatment indications. Eascra is working with NASA, the ISS National Lab, and private space company Axiom Space to accelerate our go-to-market strategy. We are actively seeking commercial partnerships with companies in need of innovative delivery mechanisms to expedite the development of cutting-edge treatments that enhance patient outcomes.

About the International Space Station (ISS) National Laboratory

The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Lab allows researchers to leverage this multiuser facility to improve life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space, Inc. (CASIS) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit [our website](#).